1 腫瘤基因檢測

目前,随着越来越多肿瘤靶向药物和免疫药物的获批上市,甚至纳入医保,基因检测已经逐渐成为肿瘤治疗的常规手段。基于这些靶向药物的多样性,临床检测需求已经从单一基因推进到了多基因平行检测——NGS检测则可以一次性检测几十甚至几百个基因,筛查全部用药的可能性,并弥补传统方法不能对免疫标志物TMB、MSI检出的不足。

查看更多
2 燃石LAVA精準診療數據社區

随着医学领域的快速发展和人们对肿瘤发病分子机制认识的不断深入,肿瘤治疗逐渐从前基因组的细胞毒性药物治疗时代过渡到后 基因组的靶向治疗新时代,并不断朝着非单一分子标记物的免疫治疗时代努力探索。随着二代测序技术(NGS)在癌症诊疗过程中发挥 越来越重要的作用,尤其是免疫检查点抑制剂要求检测包含几百个基因的大Panel,临床医生也会面临随之而来的各种困境和挑战。

查看更多
3 燃石精準臨床試驗

肿瘤药物研发已经进入精准时代,分子肿瘤学和基因组学的进步对于靶向抗肿瘤药物的研发提出了新的挑战也制造了新的机遇。燃石医学“精准研究”项目服务于药企合作伙伴以提供更优化的试验设计以及帮助招募临床试验要求的具有特定基因变异的患者从而加快临床试验进度。

查看更多

燃石医学推出Magnis BR,革新NGS检测自动化全流程

發布日期:2019-11-18

联合安捷伦共同打造的黑科技,让NGS检测走进更多医院

“INGS-燃精准,应如石”再次点燃2019 CSCO,见证中国NGS进行时

發布日期:2019-10-10

2019年9月19日,第22届临床肿瘤学大会暨2019年CSCO学术年会将在厦门隆重之际,燃石医学在厦门国际会议中心海峡厅召开“INGS——燃精准,应如石”主题卫星会

学术合作

CTONG共建NGS实验室的首家合作伙伴

2016年8月,由中國胸部腫瘤研究協作組(Chinese Thoracic Oncology Group,CTONG)和燃石醫學聯合創建的二代基因測序(NGS)臨床研究實驗室在廣州國際生物島正式落成。該實驗室將主要用于開展非營利性臨床研究。占地約3000平方米的聯合實驗室包括19間獨立實驗室和辦公區域,覆蓋樣本前處理、核酸提取、文庫構建及測序,以及數據分析和報告生成四大核心環節的完整NGS檢測流程,并采用國際一流的測序設備及國際標準的管理體系。中國臨床腫瘤學會(CSCO)理事長吳一龍教授和燃石醫學CEO漢雨生先生為聯合實驗室揭幕。

检测平台

占全球测序市场份额80%的IIIumina在中国的临床肿瘤战略合作伙伴,与IIIumina启动Miseq dx测序仪联合临床实验

2015年8月24日,燃石醫學與美國illumina公司(NASDAQ:ILMN)在中國廣州和美國圣迭戈正式宣布雙方達成戰略合作,就共同開發腫瘤個體化醫療基因檢測平臺簽訂協議。雙方將合作開發專注于中國市場的、操作簡便的腫瘤分子診斷試劑盒。作為合作的一部分,燃石醫學將提供核酸提取、文庫構建以及數據分析軟件,同時,illumina將提供二代測序儀器和相關試劑。 美國Illumina公司是全球領先的新一代高通量測序儀供應商,也是大規模分析遺傳變異和功能的生命科學工具及完整系統的領先開發商、制造商和營銷商。這些系統實現了幾年前甚至無法想象的研究,讓人們距離個性化醫療的實現更近一步。

分子诊断解决方案

燃石医学将在中国开发基于Agilent SureSelect 靶向序列捕获系统的肿瘤基因检测,为中国肿瘤患者提供更多高品质的基于二代基因测序的分子诊断解决方案

2016 年 9 月 29 日,燃石醫學與診斷與基因組學的全球領導者安捷倫科技公司(Agilent Technologies)宣布簽訂協議,根據協議,燃石醫學將在中國開發基于Agilent SureSelect 靶向序列捕獲系統的腫瘤基因檢測,為中國腫瘤患者提供更多高品質的基于二代基因測序的分子診斷解決方案,包括腫瘤無創檢測,復發監控,早期診斷和遺傳易感性篩查等。

学术合作

搭建分享、讨论真实世界精准诊疗病例的平台,共同探索未知,推进精准诊疗实践。

“斐燃成章腫瘤精準案例巡展”由燃石醫學自2017年2月發起,旨在搭建分享、討論真實世界精準診療病例的平臺,共同探索未知,推進精準診療實踐。2017年,“斐燃成章”系列活動取得圓滿成功,集合全國14個省市的40余家頂尖醫院,分享60余個真實世界案例,參與的醫學專業人士超過1500人次。 2018年,燃石醫學攜手CSCO Young、吳階平醫學基金會,進一步升級項目規模、形式和范圍,從肺癌擴展至多個癌種,從個案分享擴展至同類案例隊列,激發科研靈感,啟發對同類案例更具普適性的臨床建議。由吳一龍教授領銜、數十位專家組成的導師組,將對這些案例的完整性、典型性、啟發性等多個維度進行評選。最終選拔出的全國優秀案例將獲得“吳階平-燃石醫學青年醫師種子基金”的鼓勵。

学术合作

CSCO CAGC肺癌研究指定检测合作伙伴


CSCO(中國臨床腫瘤學會)CAGC( 中國腫瘤驅動基因分析聯盟)肺癌研究指定檢測合作伙伴

分子诊断解决方案

凯杰(QIAGEN)中国在液体活检领域战略合作伙伴,保证燃石ctDNA样本制备技术和产品质量的可靠

2018年6月5日,燃石醫學與凱杰(QIAGEN)中國達成合作協議,雙方將在循環腫瘤DNA(ctDNA)液體活檢領域展開全方位戰略合作。燃石一直不斷追求更高水平的質量標準,為醫生和患者提供值得信賴的檢測結果。QIAGEN 的ctDNA樣本制備技術和產品質量可靠,純化效率高,能幫助我們提高檢測樣本的核酸提取質量,從而使得檢測結果更加準確。相信通過兩家公司的強強聯手,能為中國廣大醫生和患者帶來高品質的基于二代基因測序的腫瘤分子診斷解決方案。

精准用药

阿斯利康肺癌NGS检测唯一战略伙伴,代表NGS方法学参与ASTRIS研究,参与L-moca奥拉帕利中国四期临床研究(HRD)

2016年,燃石醫學與阿斯利康中國達成戰略合作,燃石醫學成為阿斯利康肺癌NGS檢測戰略伙伴。 2017年初,燃石醫學攜手中國婦女發展基金會與阿斯利康中國,推出中國卵巢癌領域首個NGS慈善公益項目—— “檢愛?遇見未知的自己”BRCA卵巢癌慈善關愛項目。

1 Tumor Genetic Testing

At present, with more and more tumor targeted drugs and immune drugs approved for marketing and even included in medical insurance, genetic testing has gradually become a routine means of cancer treatment. Based on the diversity of these targeted drugs, clinical testing needs have evolved from a single gene to a multi-gene parallel test—NGS testing...

More
2 Burning Rock LAVA precision diagnosis & treatment data community

As medicine is booming and people go deeper in understanding the molecular mechanism for cancers, cancer treatment has evolved step by step from pregenome-based cytotoxic drug therapy to genome-based targeted therapy with constant efforts of probing into immunotherapy targeting multiple molecular markers. As the Next-Generation Sequencing (NGS) tec...

More
3 Burning Rock Precision Clinical Test

Research and development of cancer drug has embarked on a precision era. In this era, the progress in molecular oncology and genomics indicates a new challenge and opportunity in research and development of targeted anti-cancer drugs. Burning Rock “precision research” program therein takes aim at speeding up clinical tests by optimizing test design...

More

Burning Rock Dx Launches Magnis BR to Innovate Total Process Automation for NGS Testing

Var Date:2019-11-18

Exclusively supported by Agilent, this futuristic technology brings NGS testing to more hospitals

Burning Rock announces the completion of the Series C financing of RMB 850 million and strives to build an international leading tumor precision medicine brand

Var Date:2019-08-23

On February 14, 2019, Burning Rock held the signing ceremony and announced the closing of the Series C financing totaling RMB 850 million.

Academic Cooperation

CTONG's First Partner for Founding NGS Lab

In August 2016, Co-founded by Chinese Thoracic Oncology Group (CTONG) and Burning Rock Dx, the Next Generation Sequencing (NGS) Clinical Research Lab was duly inaugurated at Guangzhou International Bio Island. This lab is intended for non-profit clinical studies. The 3,000m2 lab comprises 19 independent labs and an office area, covers an intact NGS test process from sample library preparation, nucleic acid extraction, library building & sequencing to data analysis & report generating inclusive, adopts world-class sequencing equipment and complies with international standard management systems. Professor Wu Yilong, President Elect of Chinese Society of Clinical Oncology (CSCO), and Mr. Han Yusheng, CEO of Burning Rock Dx, unveiled a plaque to mark the inauguration of the lab.

Detection Platform

Burning Rock and America illumina Co. (NASDDAQ: ILMN) declared a strategic cooperation in Guangzhou and San Diego officially and signed an agreement on jointly developing a tumor individualistic medical gene detection.

On August 24, 2015, Burning Rock and America illumina Co. (NASDDAQ: ILMN) declared a strategic cooperation in Guangzhou and San Diego officially and signed an agreement on jointly developing a tumor individualistic medical gene detection. Both sides will cooperate to develop a tumor molecular diagnosis kit geared to Chinese market and easy to operate. As part of their cooperation, Burning Rock will provide nucleic acid extraction, construction of gene bank and data analysis software, while illumina will provide NGS instrument and related reagents. America illumina Co. is a globally leading supplier of new generation of high-flux sequencing instrument, and a leading developer, manufacturer and marketer of life science kit and complete system used to analyze hereditary mutations and functions on a large scale. These systems have realized researches which we could not imagine years ago and made us nearer to the fulfillment of individualistic medicine.

Molecular Diagnostics Solutions

Burning Rock Dx is planning to develop genetic cancer testing based on the Agilent SureSelect targeting sequence capture system in China to provide more high-quality NGS-based molecular diagnostics solutions for Chinese cancer patients

On September 29, 2016, Burning Rock Dx announced the conclusion of an agreement with a global diagnostics and genomics leader Agilent Technologies. As agreed, Burning Rock Dx is planned to develop genetic cancer testing based on the Agilent SureSelect targeting sequence capture system in China to provide more high-quality NGS-based molecular diagnostics solutions for Chinese cancer patients, including noninvasive cancer testing, recurrence monitoring, early diagnosis and genetic susceptibility screening among others.

Academic Cooperation

For building a platform for sharing and discussing precision diagnosis and treatment cases in real world, probing into the unknown and promoting precision diagnosis and treatment practice.

Initiated by Burning Rock Dx in February 2017, “FeiRanChengZhang Anti-cancer Precision Medicine Case Roadshow” was aimed at setting up a platform for sharing and discussion precision diagnosis and treatment cases in real world, probing into the unknown and promoting precision diagnosis and treatment practice. In 2017, the “FeiRanChengZhang” roadshow ended up with success. The roadshow involved 1,500+ medical professionals from 40+ top hospitals in 14 provinces and municipalities nationwide, where 60+ real world cases were shared. In 2018, Burning Rock Dx partnered with CSCO Young and Wu Jieping Medical Foundation to escalate the roadshow project in size, form and range. By expanding from lung cancer to a variety of cancers and from case sharing to similar case arraying, the project was redesigned to inspire inspiration in scientific research and more universal clinical advice to cases of the like. For that end, a panel of dozens of specialists led by Professor Wu Yilong will evaluate cases from a variety of dimensions including integrity, typicality, inspiration, etc. Finalized national outstanding cases will be granted with an incentive from “Wu Jieping-Burning Rock Dx Young Physician Seed Fund”.

Academic Cooperation

Designated testing partner to CSCO and CAGC in lung cancer research

Molecular Diagnostics Solutions

Burning Rock’s reassuring strategic partner in liquid biopsy - QIAGEN China with ctDNA sample preparation technology and high product quality

On June 5, 2018, Burning Rock Dx agreed with QIAGEN China to establish a strategic partnership in liquid biopsy for circulating tumor DNA (ctDNA) in all respects. Burning Rock keeps demanding on quality to offer testing results that can be trusted by doctors and patients. QIAGEN, with its ctDNA sample preparation technology and high product quality and purification efficiency can help Burning Rock improve quality of nucleic acid extracted from samples to produce more accurate testing results. It is believed that the two firms together can introduce high-quality NGS-based anti-cancer molecular diagnostics solutions to doctors and patients in China.

Precision Medicine

AstraZeneca's sole strategic NGS lung cancer testing partner involved in ASTRIS research and L-moca Olaparib stage-IV clinical research (HRD) in China

In 2016, Burning Rock Dx turned into AstraZeneca's lung cancer NGS testing partner by concluding a strategic partnership with AstraZeneca China. Earlier in 2017, Burning Rock Dx co-launched China's first non-profit NGS project targeting ovarian cancer-- ”Love Me, Test Me” public-welfare BRCA testing project for ovarian cancer patients.